Trial · NCT00095238
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints | Year 1, Year 2, Year 3, Year 4, Year 5 | Randomized Participants | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time Points | Year 1, Year 2, Year 3, Year 4, Year 5 | Randomized Participants | percentage of participants | NUMBER |
| SECONDARY | Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Month 6 and Month 14 | Baseline, Month 6, Month 14 | Participants with baseline score and score at timepoint. | units on a scale | MEAN |
| SECONDARY | Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Final Visit | Baseline, Final Visit=last scheduled visit specified in the protocol at conclusion of the entire study by the sponsor. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years. | Participants with baseline score and score at timepoint. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in B-Type Natriuretic Peptide (Pro-BNP) at Month 6 and Month 14 | Baseline, Month 6, Month 14 | number of participants with measurement at baseline and at timepoint | pg/mL | GEOMETRIC_MEAN |
| SECONDARY | Percentage of Participants Experiencing CV Death, Non-Fatal Myocardial Infarction (MI), or Non-Fatal Stroke at Given Timepoints | Year 1, Year 2, Year 3, Year 4, Year 5 | Randomized Participants | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Experiencing Cardiovascular Death at Given Timepoints | Year 1, Year 2, Year 3, Year 4, Year 5 | Randomized Subjects | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Experiencing All-cause Death at Given Time Points | Year 1, Year 2, Year 3, Year 4, Year 5 | Randomized subjects | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in the New York Heart Association (NYHA) Functional Class at Month 6, Month 10, Month 14, and Final Visit | Baseline, Month 6, Month 10, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years. | Randomized participants with measurement at baseline and Month 6, Month 10, Month 14, and Final Visit | participants | NUMBER |
| SECONDARY | Physician Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline | Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years. | participants | NUMBER | |
| SECONDARY | Participant Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline | Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years. | Randomized Participants | Participants | NUMBER |
| SECONDARY | Participant Assessment of Fatigue at Month 6, Month 14, and Final Visit Compared With Baseline | Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years. | Randomized Participants | Participants | NUMBER |
| SECONDARY | Participant Assessment of Dyspnea at Month 6, Month 14, and Final Visit Compared With Baseline | Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years. | Randomized Participants | Participants | NUMBER |
| SECONDARY | Percentage of Participants Experiencing CV Death or CV Hospitalization at Given Timepoints | Year 1, Year 2, Year 3, Year 4, Year 5 | randomized participants | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Experiencing Protocol-specified Cardiovascular (CV) Hospitalization at Given Timepoints | Year 1, Year 2, Year 3, Year 4, Year 5 | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants With New Onset of Diabetes Among Subjects With No Prior Diabetes History at Given Timepoints | Year 1, Year 2, Year 3, Year 4, Year 5 | Randomized participants with no prior diabetes history | percentage of participants | NUMBER |
| SECONDARY | Mean Change From Baseline in Glomerular Filtration Rate (GFR) at Month 6, Month 18, and Month 30 | Baseline, Month 6, Month 18, Month 30 | Participants with baseline score and score at timepoint. | mL/min/1.73m2 | MEAN |
| SECONDARY | Mean Change From Baseline in Glomerular Filtration Rate (GFR)at Month 42, Month 54, Month 66 | Baseline, Month 42, Month 54, Month 66 | Participants with baseline score and score at timepoint. | mL/min/1.73m2 | MEAN |
| SECONDARY | Number of Participants With New Onset Atrial Fibrillation (AF) Among Those With No Prior AF History or Evidence of AF on Baseline Electrocardiograph (ECG) | Baseline, Final Visit | Randomized subjects (total=4128) with no prior AF history or evidence of AF on baseline ECG, stratified by use of ACE-I | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00095238/outcomes